A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease

Next Previous
Trial Profile

A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Adipose-derived stem cells-UnicoCell (Primary)
  • Indications Renal failure
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors UnicoCell Biomed

    • Most Recent Events

    • 24 Oct 2017 Planned initiation date changed from 1 Dec 2016 to 1 Mar 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 21 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top